Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 9(57), p. 4554-4558, 2013

DOI: 10.1128/aac.00283-13

Links

Tools

Export citation

Search in Google Scholar

Evaluation of Combinations of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine with Clinically Used Antiretroviral Drugs

Journal article published in 2013 by Atsuko Hachiya, Aaron B. Reeve, Bruno Marchand, Eleftherios Michailidis, Yee Tsuey Ong, Karen A. Kirby, Maxwell D. Leslie, Shinichi Oka ORCID, Eiichi N. Kodama, Lisa C. Rohan, Hiroaki Mitsuya, Michael A. Parniak, Stefan G. Sarafianos
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT Drug combination studies of 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) with FDA-approved drugs were evaluated by two different methods, MacSynergy II and CalcuSyn. Most of the combinations, including the combination of the two adenosine analogs EFdA and tenofovir, were essentially additive, without substantial antagonism or synergism. The combination of EFdA and rilpivirine showed apparent synergism. These studies provide information that may be useful for the design of EFdA combination regimens for initial and salvage therapy assessment.